{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:28:05Z","timestamp":1792898885243,"version":"4.5.0"},"reference-count":108,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Progress in the therapy of follicular lymphoma (FL), the most common indolent lymphoma subtype, has been achieved in recent years with significant improvement in median overall survival. Most patients diagnosed with FL will now die from other causes. Multiple novel immunotherapy and other targeted therapies are now approved for relapsed and refractory disease. However, early progression and transformation to aggressive lymphoma remain key issues requiring further innovation. We expect that bispecific antibodies will likely move to earlier use and in novel combinations. Future generations of these and chimeric antigen receptor T-cell therapy will be developed in an effort to minimize toxicity and improve efficacy. New technologies, such as circulating tumor DNA assays, may enable more rational selection and guidance of therapy duration or changes in treatment, as well as possibly substituting for follow-up imaging while monitoring patients. We also look forward to more extensive use of quality-of-life tools to select treatment for patients who have a favorable long-term outlook with multiple options. Finally, patients and clinicians now envision a day when FL is no longer referred to as \u201cincurable.\u201d Having a definition and possibility of a \u201ccure\u201d and being able to optimize such a mindset in the approach of FL would represent a major advance in our future management strategy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024026017","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T10:28:34Z","timestamp":1740738514000},"page":"1792-1801","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["The future of follicular lymphoma management: strategies on the horizon"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4042-8875","authenticated-orcid":false,"given":"Erin","family":"Mulvey","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology, Weill Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-7727","authenticated-orcid":false,"given":"Sarah C.","family":"Rutherford","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Weill Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5083-1115","authenticated-orcid":false,"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Weill Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2025100911215389900_bib1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"issue":"28","key":"2025100911215389900_bib2","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025100911215389900_bib3","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.23.01912","article-title":"Long-term follow-up of the RESORT study (E4402): a randomized phase III comparison of two different rituximab dosing strategies for low-tumor burden follicular lymphoma","volume":"42","author":"Kahl","year":"2024","journal-title":"J Clin Oncol"},{"issue":"15","key":"2025100911215389900_bib4","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9873","key":"2025100911215389900_bib5","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"2025100911215389900_bib6","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"14","key":"2025100911215389900_bib7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"2025100911215389900_bib8","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.bbmt.2017.05.021","article-title":"Autologous stem cell transplantation for follicular lymphoma: favorable long-term survival irrespective of pretransplantation rituximab exposure","volume":"23","author":"Jimenez-Ubieto","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"issue":"14","key":"2025100911215389900_bib9","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025100911215389900_bib10","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"2025100911215389900_bib11","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"5","key":"2025100911215389900_bib12","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"issue":"27","key":"2025100911215389900_bib13","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025100911215389900_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2025100911215389900_bib15","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025100911215389900_bib16","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"issue":"9383","key":"2025100911215389900_bib17","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"10","key":"2025100911215389900_bib18","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.3324\/haematol.2023.284538","article-title":"Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study","volume":"109","author":"Barraclough","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"2025100911215389900_bib19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41408-024-01111-w","article-title":"Identification of genetic subtypes in follicular lymphoma","volume":"14","author":"Shelton","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5","key":"2025100911215389900_bib20","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"issue":"15","key":"2025100911215389900_bib21","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","article-title":"Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008","volume":"121","author":"Morton","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2025100911215389900_bib22","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/bloodadvances.2023011305","article-title":"Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience","volume":"8","author":"Shotton","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2025100911215389900_bib23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjh.19407","article-title":"Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: an Australasian Lymphoma Alliance study","volume":"205","author":"Manos","year":"2024","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2025100911215389900_bib24","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2024-211926","article-title":"Subsequent primary malignancies in patients with indolent B cell non-Hodgkin lymphoma receiving frontline bendamustine rituximab therapy [abstract]","volume":"144","author":"Davies","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025100911215389900_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025100911215389900_bib26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"key":"2025100911215389900_bib27","unstructured":"National Comprehensive Cancer Network. B cell lymphomas. Version 3.2024. Accessed 21 October 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1480."},{"issue":"8","key":"2025100911215389900_bib28","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"19","key":"2025100911215389900_bib29","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable responses with mosunetuzumab in relapsed\/refractory indolent and aggressive B-cell non-Hodgkin lymphomas: extended follow-up of a phase I\/II study","volume":"42","author":"Budde","year":"2024","journal-title":"J Clin Oncol"},{"issue":"23","key":"2025100911215389900_bib30","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025100911215389900_bib31","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025100911215389900_bib32","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-017-01029-x","article-title":"EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop","volume":"8","author":"Beguelin","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"2025100911215389900_bib33","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1038\/bcj.2017.32","article-title":"EZH2 alterations in follicular lymphoma: biological and clinical correlations","volume":"7","author":"Huet","year":"2017","journal-title":"Blood Cancer J"},{"issue":"4","key":"2025100911215389900_bib34","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"2025100911215389900_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","article-title":"EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function","volume":"43","author":"Isshiki","year":"2025","journal-title":"Cancer Cell"},{"issue":"11","key":"2025100911215389900_bib36","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1111\/cas.15122","article-title":"The EZH2 inhibitor tazemetostat upregulates the expression of CCL17\/TARC in B-cell lymphoma and enhances T-cell recruitment","volume":"112","author":"Yuan","year":"2021","journal-title":"Cancer Sci"},{"issue":"18","key":"2025100911215389900_bib37","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025100911215389900_bib38","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"2025100911215389900_bib39","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.annonc.2024.11.009","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"36","author":"Kim","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"2025100911215389900_bib40","doi-asserted-by":"crossref","first-page":"1890411","DOI":"10.1080\/19420862.2021.1890411","article-title":"TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL","volume":"13","author":"Malik-Chaudhry","year":"2021","journal-title":"MAbs"},{"issue":"16_suppl","key":"2025100911215389900_bib41","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.7524","article-title":"High complete response rate with TNB-486 in relapsed\/refractory follicular lymphoma: interim results from an ongoing phase 1 study [abstract]","volume":"41","author":"Nair","year":"2023","journal-title":"J Clin Oncol"},{"issue":"21","key":"2025100911215389900_bib42","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2023023381","article-title":"CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy","volume":"143","author":"Sam","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025100911215389900_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2025100911215389900_bib44","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2025100911215389900_bib45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"2025100911215389900_bib46","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"17","key":"2025100911215389900_bib47","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2025100911215389900_bib48","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"2025100911215389900_bib49","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12943-023-01886-9","article-title":"Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol Cancer"},{"issue":"16_suppl","key":"2025100911215389900_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7579","article-title":"ZUMA-22: a phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R\/R) follicular lymphoma (FL) [abstract]","volume":"41","author":"Flinn","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025100911215389900_bib51","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jcyt.2023.03.011","article-title":"Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness","volume":"25","author":"Lau","year":"2023","journal-title":"Cytotherapy"},{"issue":"16_suppl","key":"2025100911215389900_bib52","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.7025","article-title":"A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed\/refractory B cell non-Hodgkin lymphoma (r\/r B-NHL): updated phase 1 results from the ANTLER trial [abstract]","volume":"42","author":"Hu","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025100911215389900_bib53","doi-asserted-by":"crossref","first-page":"1005457","DOI":"10.3389\/fimmu.2022.1005457","article-title":"Practical aspects of chimeric antigen receptor T-cell administration: from commercial to point-of-care manufacturing","volume":"13","author":"Martinez-Cibrian","year":"2022","journal-title":"Front Immunol"},{"key":"2025100911215389900_bib54","unstructured":"Lymphoma Research Foundation. Adherence and oral therapies in lymphoma and CLL. 2018. Accessed 24 October 2024. https:\/\/lymphoma.org\/wp-content\/uploads\/2018\/03\/6609-LRF-Oral-Therapies-White-Paper-Final2-Web-03_14.pdf."},{"issue":"17","key":"2025100911215389900_bib55","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/cam4.4692","article-title":"Patient-reported outcomes provide prognostic information for survival in patients with diffuse large B-cell lymphoma: analysis of 1239 patients from the GOYA study","volume":"11","author":"Huang","year":"2022","journal-title":"Cancer Med"},{"issue":"7","key":"2025100911215389900_bib56","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2017-03-737403","article-title":"Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?","volume":"130","author":"Efficace","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2025100911215389900_bib57","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"key":"2025100911215389900_bib58","doi-asserted-by":"crossref","first-page":"100994","DOI":"10.1016\/j.blre.2022.100994","article-title":"Targeting cereblon in hematologic malignancies","volume":"57","author":"Fuchs","year":"2023","journal-title":"Blood Rev"},{"issue":"suppl 1","key":"2025100911215389900_bib59","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1182\/blood-2023-188771","article-title":"Efficacy and safety of golcadomide, a novel cereblon E3 ligase modulator (CELMoD) agent, combined with rituximab in a phase 1\/2 open-label study of patients with relapsed\/refractory non-Hodgkin lymphoma [abstract]","volume":"142","author":"Chavez","year":"2023","journal-title":"Blood"},{"issue":"33","key":"2025100911215389900_bib60","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025100911215389900_bib61","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2023-181309","article-title":"Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed\/refractory follicular lymphoma: results from the phase 1\/2 BRUIN study [abstract]","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025100911215389900_bib62","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2023-180109","article-title":"First results from a phase 1, first-in-human study of the Bruton\u2019s tyrosine kinase (BTK) degrader Bgb-16673 in patients (pts) with relapsed or refractory (R\/R) B-cell malignancies (BGB-16673-101) [abstract]","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025100911215389900_bib63","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2024-210951","article-title":"BMS-986458 a potential first-in-class, highly selective, potent and well tolerated BCL6 ligand directed degrader (LDD) demonstrates multi-modal anti-tumor efficacy for the treatment of B-cell non-Hodgkin\u2019s lymphoma [abstract]","volume":"144","author":"Groocock","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2025100911215389900_bib64","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"2025100911215389900_bib65","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025100911215389900_bib66","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ajh.25711","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study","volume":"95","author":"Dreyling","year":"2020","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2025100911215389900_bib67","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1182\/blood-2023-179910","article-title":"Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed\/refractory follicular lymphoma: updated phase 1b results of Symphony-1 with 22.5 months follow-up [abstract]","volume":"142","author":"Salles","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2025100911215389900_bib68","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/acs.jmedchem.7b01375","article-title":"Optimization of orally bioavailable enhancer of zeste homolog 2 (EZH2) inhibitors using ligand and property-based design strategies: identification of development candidate (R)-5,8-dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)","volume":"61","author":"Kung","year":"2018","journal-title":"J Med Chem"},{"issue":"7","key":"2025100911215389900_bib69","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S2352-3026(22)00134-X","article-title":"SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial","volume":"9","author":"Song","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"2025100911215389900_bib70","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2016.154377","article-title":"Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study","volume":"102","author":"Ribrag","year":"2017","journal-title":"Haematologica"},{"issue":"16_suppl","key":"2025100911215389900_bib71","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.7059","article-title":"A phase II multicenter study of abexinostat, an oral histone deacetylase inhibitor, in patients with relapsed\/refractory follicular lymphoma [abstract]","volume":"42","author":"Shi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025100911215389900_bib72","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood-2023-179304","article-title":"Efficacy and safety of valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: primary results of the phase 2 VALENTINE-PTCL01 study","volume":"142","author":"Horwitz","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025100911215389900_bib73","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood-2023-179301","article-title":"Valemetostat for relapsed or refractory B-cell lymphomas: primary results from a phase 1 trial","volume":"142","author":"Izutsu","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2025100911215389900_bib74","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"2025100911215389900_bib75","doi-asserted-by":"crossref","first-page":"LBA-1","DOI":"10.1182\/blood-2024-212970","article-title":"Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: results from a phase 3 study (inMIND) [abstract]","volume":"144","author":"Sehn","year":"2024","journal-title":"Blood"},{"issue":"18","key":"2025100911215389900_bib76","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"2025100911215389900_bib77","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1182\/bloodadvances.2024013277","article-title":"Magrolimab plus rituximab in relapsed\/refractory indolent non-Hodgkin lymphoma: phase 1\/2 trial 3-year follow-up","volume":"8","author":"Mehta","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2025100911215389900_bib78","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1158\/1078-0432.CCR-19-2973","article-title":"First-in-human study of utomilumab, a 4-1BB\/CD137 agonist, in combination with rituximab in patients with follicular and other CD20(+) non-Hodgkin lymphomas","volume":"26","author":"Gopal","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025100911215389900_bib79","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00277-023-05475-0","article-title":"A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed\/refractory follicular lymphoma","volume":"103","author":"Merryman","year":"2024","journal-title":"Ann Hematol"},{"issue":"2","key":"2025100911215389900_bib80","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025100911215389900_bib81","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"2025100911215389900_bib82","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/leu.2015.48","article-title":"Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes","volume":"29","author":"Pfeifer","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"2025100911215389900_bib83","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00432-021-03847-5","article-title":"Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed\/refractory follicular and diffuse large B-cell lymphoma","volume":"149","author":"Topp","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"2025100911215389900_bib84","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1016\/S2352-3026(21)00311-2","article-title":"Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b\/2 study","volume":"8","author":"Diefenbach","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"2025100911215389900_bib85","first-page":"1194","article-title":"Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed\/refractory follicular lymphoma: a phase Ib\/II study","volume":"109","author":"Flowers","year":"2024","journal-title":"Haematologica"},{"issue":"19","key":"2025100911215389900_bib86","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025100911215389900_bib87","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3026(24)00345-4","article-title":"Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial","volume":"12","author":"Alderuccio","year":"2025","journal-title":"Lancet Haematol"},{"issue":"15","key":"2025100911215389900_bib88","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1182\/bloodadvances.2022007792","article-title":"Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma","volume":"8","author":"Ramirez","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2025100911215389900_bib89","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/sj.leu.2401575","article-title":"Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD)","volume":"13","author":"Olsson","year":"1999","journal-title":"Leukemia"},{"issue":"12","key":"2025100911215389900_bib90","first-page":"3243","article-title":"Frequency and structure of t(14;18) major breakpoint regions in non-Hodgkin's lymphomas typed according to the Kiel classification: analysis by direct DNA sequencing","volume":"51","author":"Kneba","year":"1991","journal-title":"Cancer Res"},{"issue":"7","key":"2025100911215389900_bib91","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.21.01234","article-title":"Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study","volume":"40","author":"Luminari","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025100911215389900_bib92","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.leu.2404479","article-title":"Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 concerted action BHM4-CT98-3936","volume":"21","author":"Evans","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"2025100911215389900_bib93","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"5","key":"2025100911215389900_bib94","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"364","key":"2025100911215389900_bib95","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"1","key":"2025100911215389900_bib96","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","article-title":"Circulating tumor DNA in lymphoma: principles and future directions","volume":"3","author":"Roschewski","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2025100911215389900_bib97","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-22-1654","article-title":"Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a prospective pilot study","volume":"29","author":"Fernandez-Miranda","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2025100911215389900_bib98","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/s41375-022-01618-w","article-title":"Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research","volume":"36","author":"Lauer","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"2025100911215389900_bib99","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JOP.19.00691","article-title":"Potential of circulating tumor DNA for the management of patients with lymphoma","volume":"16","author":"Huet","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"2025100911215389900_bib100","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025100911215389900_bib101","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood-2021-151096","article-title":"A prospective study of clonal evolution in follicular lymphoma: circulating tumor DNA correlates with overall tumor burden and fluctuates over time without therapy [abstract]","volume":"138","author":"Distler","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2025100911215389900_bib102","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood.2020008243","article-title":"Is it time for PET-guided therapy in follicular lymphoma?","volume":"139","author":"Trotman","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2025100911215389900_bib103","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","article-title":"Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial","volume":"20","author":"Galimberti","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2025100911215389900_bib104","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2023-178030","article-title":"Combining PET\/CT and ctDNA assessments at 6 months from induction treatment better predicts outcome in previously untreated patients with follicular lymphoma: a relevance ancillary Lysa study [abstract]","volume":"142","author":"Claudel","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2025100911215389900_bib105","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1200\/JCO.21.02477","article-title":"Response-adapted therapy in follicular lymphoma: at the threshold of a precision approach","volume":"40","author":"Casulo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"18","key":"2025100911215389900_bib106","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1002\/cncr.33660","article-title":"Surveillance imaging during first remission in follicular lymphoma does not impact overall survival","volume":"127","author":"Goldman","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"2025100911215389900_bib107","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s41687-024-00708-w","article-title":"Are changes in patient-reported outcomes prognostic for diffuse large B-cell lymphoma survival? Results from the GOYA trial","volume":"8","author":"Yan","year":"2024","journal-title":"J Patient Rep Outcomes"},{"issue":"23","key":"2025100911215389900_bib108","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1182\/bloodadvances.2020002858","article-title":"Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35\/03 randomized trial","volume":"4","author":"Moccia","year":"2020","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/15\/1792\/2415839\/blood_bld-2024-026017-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/15\/1792\/2415839\/blood_bld-2024-026017-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:22:09Z","timestamp":1760023329000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/15\/1792\/535794\/The-future-of-follicular-lymphoma-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":108,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,10,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026017","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,9]]},"published":{"date-parts":[[2025,10,9]]}}}